Management of Celiac Disease with Positive IgA but Negative Anti-TTG

Diagnostic Approach for Discordant Results

For patients with positive IgA but negative anti-TTG results, the American Gastroenterological Association recommends a comprehensive diagnostic evaluation, including HLA testing, duodenal biopsy while on a gluten-containing diet, and consideration of seronegative celiac disease if villous atrophy is present 1, 2
The patient should be confirmed to be on a gluten-containing diet, as gluten avoidance can lead to false-negative serologic results, according to the American Gastroenterological Association 1, 3
Total IgA levels should be measured to rule out IgA deficiency, which could explain negative anti-TTG IgA results, as suggested by the American Gastroenterological Association 1, 2
A full celiac serology panel, including anti-TTG IgA, deamidated gliadin peptide (DGP) IgA, and endomysial antibody (EMA) IgA, should be completed, as recommended by the American Gastroenterological Association 1, 4
HLA-DQ2 and HLA-DQ8 genetic markers should be tested, as negative results can effectively rule out celiac disease in seronegative patients, according to the American Gastroenterological Association 1, 2
Upper endoscopy and multiple duodenal biopsies (ideally 6 specimens) from the second part of the duodenum or beyond should be performed, regardless of serologic results if clinical suspicion is high, as recommended by the American Gastroenterological Association 5, 3

The American Gastroenterological Association recommends verifying that the patient was consuming adequate gluten (at least 10g daily for 6-8 weeks) before testing, and reviewing medication history for drugs that may affect results (e.g., immunosuppressants) 1, 2
If biopsy shows villous atrophy, with positive HLA-DQ2/DQ8, the American Gastroenterological Association suggests considering seronegative celiac disease 1, 2
If seronegative celiac disease is suspected, the American Gastroenterological Association recommends initiating a strict gluten-free diet, performing follow-up endoscopy after 1-3 years to assess histologic improvement, and confirming diagnosis based on clinical and histologic improvement on gluten-free diet 1, 2

The American Gastroenterological Association warns that relying solely on serologic testing without biopsy confirmation can lead to misdiagnosis, especially with discordant results, and that other causes of villous atrophy must be considered in seronegative patients 1, 4
Patients with persistent symptoms who don't respond to a gluten-free diet, and for whom no etiology of enteropathy is identified, may benefit from budesonide treatment, as suggested by the American Gastroenterological Association 1, 2

The American Gastroenterological Association recommends considering testing for other associated conditions, particularly in high-risk groups, such as iron deficiency anemia, premature osteoporosis, autoimmune thyroid disease, type 1 diabetes, and first-degree relatives of patients with celiac disease 6, 7

The American Gastroenterological Association recommends reviewing medication history, as angiotensin II receptor blockers and immunosuppressants can cause villous atrophy or affect test results, with a strength of evidence based on clinical observations 8
The American Gastroenterological Association suggests that histologic interpretation should be performed by pathologists specializing in gastroenterology to avoid missing subtle changes, with a moderate level of evidence based on expert consensus 8
If HLA testing is negative, celiac disease is excluded and alternative diagnoses should be pursued, with a high level of evidence based on genetic studies 8
Consider seronegative celiac disease if biopsy shows villous atrophy with positive HLA-DQ2/DQ8, with a moderate level of evidence based on clinical case series 8
Medication-induced enteropathy, particularly olmesartan, should be considered as an alternative diagnosis when serology and histology remain discordant, with a moderate level of evidence based on clinical reports 8
If no etiology is identified and symptoms persist despite gluten-free diet trial, consider empiric treatment with budesonide, with a low level of evidence based on anecdotal experience 8